Jpmorgan Chase & CO Amicus Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,894,284 shares of FOLD stock, worth $34.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,894,284

Previous 7,214,250 32.16%

Holding current value

$34.2 Million

Previous $68 Million 41.23%

% of portfolio

0.0%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$8.16 - $9.85 $18.9 Million - $22.9 Million	-2,319,966 Reduced 32.16%	4,894,284 $39.9 Million
Q4 2024 Feb 12, 2025	SELL	$9.36 - $12.01 $53.4 Million - $68.5 Million	-5,705,679 Reduced 44.16%	7,214,250 $68 Million
Q3 2024 Dec 26, 2024	SELL	$9.55 - $12.09 $18.6 Million - $23.6 Million	-1,950,851 Reduced 13.12%	12,919,929 $138 Million
Q3 2024 Nov 08, 2024	SELL	$9.55 - $12.09 $18.6 Million - $23.6 Million	-1,950,851 Reduced 13.12%	12,919,929 $138 Million
Q2 2024 Dec 26, 2024	BUY	$9.04 - $11.75 $17.6 Million - $22.9 Million	1,950,851 Added 15.1%	14,870,780 $148 Million
Q2 2024 Aug 12, 2024	SELL	$9.04 - $11.75 $7.42 Million - $9.64 Million	-820,377 Reduced 5.23%	14,870,780 $148 Million
Q1 2024 Dec 26, 2024	BUY	$11.43 - $14.24 $31.7 Million - $39.5 Million	2,771,228 Added 21.45%	15,691,157 $185 Million
Q1 2024 May 10, 2024	SELL	$11.43 - $14.24 $24.7 Million - $30.7 Million	-2,157,374 Reduced 12.09%	15,691,157 $185 Million
Q4 2023 Dec 26, 2024	BUY	$9.97 - $14.52 $49.1 Million - $71.6 Million	4,928,602 Added 38.15%	17,848,531 $253 Million
Q4 2023 Feb 12, 2024	BUY	$9.97 - $14.52 $48.2 Million - $70.3 Million	4,839,102 Added 37.2%	17,848,531 $253 Million
Q3 2023 Nov 14, 2023	SELL	$11.78 - $13.86 $5.1 Million - $6 Million	-432,962 Reduced 3.22%	13,009,429 $158 Million
Q2 2023 Aug 11, 2023	SELL	$10.72 - $13.3 $3.12 Million - $3.87 Million	-291,094 Reduced 2.12%	13,442,391 $169 Million
Q1 2023 May 18, 2023	BUY	$10.91 - $13.54 $3.64 Million - $4.52 Million	333,726 Added 2.49%	13,733,485 $152 Million
Q1 2023 May 11, 2023	SELL	$10.91 - $13.54 $1.61 Million - $2 Million	-147,609 Reduced 1.09%	13,399,759 $149 Million
Q4 2022 Feb 13, 2023	SELL	$9.89 - $12.7 $7.82 Million - $10 Million	-790,337 Reduced 5.51%	13,547,368 $165 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $15 Million - $19.5 Million	-1,526,402 Reduced 9.62%	14,337,705 $150 Million
Q2 2022 Aug 11, 2022	BUY	$6.23 - $11.12 $1.95 Million - $3.47 Million	312,291 Added 2.01%	15,864,107 $170 Million
Q1 2022 May 11, 2022	BUY	$7.89 - $12.48 $1.64 Million - $2.6 Million	207,988 Added 1.36%	15,551,816 $147 Million
Q4 2021 Feb 10, 2022	BUY	$9.82 - $12.44 $596,761 - $755,978	60,770 Added 0.4%	15,343,828 $177 Million
Q3 2021 Nov 12, 2021	BUY	$8.74 - $11.84 $134 Million - $181 Million	15,283,058 New	15,283,058 $146 Million

Others Institutions Holding FOLD

# of Institutions

300

Shares Held

332M

Call Options Held

396K

Put Options Held

249K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $1.96B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Amicus Therapeutics, Inc. Transaction History